Menopause weight gain and GLP-1 medications

The clearest data come from SWAN, the Study of Women's Health Across the Nation, which has followed a diverse group of US women through midlife since the 1990s. A 2019 SWAN analysis measured body composition by DXA scan in 1,246 women. Before the transition, both fat and lean mass were rising slowly. Once the transition began, the rate of fat gain doubled and lean mass started to decline. Those changes continued until about two years after the final menstrual period, then leveled off.

The surprising part is what happened to the scale. Weight kept rising at the same steady pace it had before the transition, with no visible acceleration, and flattened out afterward. Faster fat gain and a loss of lean tissue roughly balanced out.

Women are well represented in the trials behind these drugs. In the Wegovy injection weight trials, 71% of participants were female; in Zepbound's main weight-reduction trial, 68% were. Neither trial was designed to look at menopause status, so the evidence for midlife women specifically comes mostly from later analyses and clinic data.

One large real-world study from Mayo Clinic followed 1,039 adults who took tirzepatide continuously for at least a year. At 15 months, women had lost an average of 15.1% of their body weight compared with 10.7% for men. People 45 and under lost more than those 60 and over, but once other factors such as diabetes and other medications were accounted for, age was not an independent predictor while sex was.

A question that comes up often is whether menopausal hormone therapy (MHT) changes how well a GLP-1 works. The research so far comes from one group's retrospective reviews of patient records at Mayo Clinic. That is useful for generating hypotheses and not enough to answer the question.

Bone loss speeds up around menopause. In SWAN, bone density loss began about a year before the final menstrual period and was fastest from then until two years after it. Over the 10 years studied, women lost about 10.6% of lumbar spine density, most of it in that window. Higher BMI was linked to slower bone loss, which is one reason clinicians pay attention to bone when weight comes down in this stage of life.

The Wegovy label reports that in its large cardiovascular outcomes trial, more hip and pelvis fractures occurred on Wegovy than on placebo in women (1% vs 0.2%) and in patients aged 75 and older (2.4% vs 0.6%). The label does not say why. It is a reason to talk about bone health with your clinician before and during treatment, not a reason for alarm.

Muscle is the other half. SWAN shows lean mass starting to fall with the transition, and rapid weight loss on any method takes some lean tissue with it. The measures that help are the same ones that help anyone losing weight, with more reason to take them seriously now.

Perimenopause is not the end of fertility, and many women in their forties still rely on oral contraceptives. Tirzepatide (Mounjaro and Zepbound) slows stomach emptying, and its label says it may reduce the effectiveness of birth control pills. The label advises women using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Hormonal contraceptives that are not taken by mouth (such as a hormonal IUD, implant, patch or ring) should not be affected.

The Wegovy label does not carry the same contraceptive instruction, but it does advise stopping Wegovy 2 months before a planned pregnancy, and both labels say to stop the medicine when a pregnancy is recognized (the Wegovy label treats its liver-disease use differently).

Decisions about MHT, a GLP-1, or both belong with a clinician who knows your history, including your cardiovascular risk, bone health, family history, other medications and your own priorities. These are some questions worth bringing: